Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (61)	11/26/2001 5:21:24 PM
From: nigel bates	Respond to of 590

FREMONT, Calif.--(BW HealthWire)--Nov. 26, 2001--Abgenix, Inc. (Nasdaq: ABGX - news) today announced that it has exclusively in-licensed from Duke University Medical Center and Johns Hopkins University a potential new target for the treatment of cancer. This target, known as EGFrvIII, is a member of the family of epidermal growth factor receptors. Other members of this important family include Her2, the target of the marketed antibody treatment, Herceptin; and epidermal growth factor receptor (``EGFr''), the target of Abgenix's fully human monoclonal antibody, ABX-EGF, currently in co-development with Immunex Corp. in Phase II clinical trials for renal and lung cancer. The receptors EGFr and EGFrvIII differ in their expression patterns: EGFr is expressed in normal tissue while it is over-expressed in many of the most prevalent human tumor types. EGFrvIII is not expressed in normal tissue, but, to date, has been identified to be expressed in brain, breast, lung and ovarian cancer tissue. This suggests that EGFrvIII may be a more specific target for antibody-based cancer therapies. EGFrvIII was discovered by lead investigators Bert Vogelstein, M.D., Professor of Oncology at Johns Hopkins University and Darell Bigner, M.D., Ph.D., the Jones Professor of Pathology and Deputy Director of the Duke Comprehensive Cancer Center, and is the subject of several issued patents and pending patent applications. The license agreement with Duke and Hopkins provides Abgenix with worldwide exclusive rights to develop and commercialize antibody-based therapeutics to EGFrvIII. ``Because EGFrvIII expression is restricted to tumor cells, it holds promise for the development of very specific antibody treatments for cancer,'' said R. Scott Greer, chairman and chief executive officer of Abgenix. ``We continue to believe that the epidermal growth factor receptor family offers some of the most exciting targets for antibody-based cancer therapies. Antibodies to this recently discovered receptor, EGFrvIII, complement our extensive and ongoing work with ABX-EGF which binds to EGFr. EGFRvIII represents an ideal fit with our clinical oncology development programs and is an opportunity to explore other unmet medical needs in the vast area of cancer.'' The class III variant of the epidermal growth factor receptor, EGFrvIII, is characterized by a deletion in the cDNA sequence of the EGFr, resulting in the formation of a new, tumor-specific receptor (cell surface marker). This spontaneously occurring receptor is found specifically in a high percentage in brain, breast, lung and ovarian tumors and does not appear to be found on normal human tissue. It is estimated that over 150,000 cancer patients in the United States undergo treatment every year for tumors that specifically express EGFrvIII. For example, an estimated 50% of brain cancer, 50-70% of breast and ovarian cancer, and 15% of NSCLC express EGFrvIII. Abgenix and its collaborators will continue to evaluate the expression of EGFrvIII in other tumor types...

To: Icebrg who wrote (61)	11/30/2001 7:24:28 AM
From: Icebrg	Read Replies (2) \| Respond to of 590

Following Abgenix's recent conference call Adams Harkness & Hill in a research note provided the following summary regarding the company's clinical development status. - ABX-IL8: The Company plans to complete enrollment in a Phase IIb study in patients with moderate-to-severe psoriasis this year, with results expected to follow in Q2 of 2002. If the data are positive, a bridging study with an intramuscular and/or subcutaneous formulation would begin in H2 of 2002, followed by Phase III trials with the new formulation in H1 of 2003. In addition, a Phase IIa proof-of-concept trial with ABX-IL8 in rheumatoid arthritis is fully enrolled. Data are expected in Q1 of 2002 (likely January). Finally, enrollment in a Phase IIa study in patients with COPD is expected to be complete by Q3 of 2002, with data to follow in Q1 of 2003. - ABX-EGF: Phase II trials with ABX-EGF continue in kidney cancer and NSCLC. A third Phase II trial will be initiated with collaborator Immunex by the end of this year (likely in colorectal or pancreatic cancer). Two additional Phase II studies are expected to begin in 2002 for other EGF-expressing cancers. Results from the Phase II trial in kidney cancer are expected by the middle of 2002. - ABX-CBL: Enrollment in the Phase II/III graft-versus-host disease trial is expected to be complete by the end of 2002, with data available in Q1 of 2003. - An IND for the fourth Abgenix product is to be filed by the end of this year. - The Company expects to have 11 product candidates by the end of 2002, seven of which will be in Phase II or Phase III trials, and 18 product candidates by the end of 2003, 11 of which will be in Phase II or Phase III trials. The staggering number of product candidates in the clinic towards the end of 2002 includes products being developed by Abgenix's licencees. Still, it is not a bad figure. Ice